Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3915803 | 1.00 | MAPT (0.43) | MAPTMAPK1KMT2AALDH1A1MEN1 | |
| SCHEMBL584707 | 0.90 | HTT (0.55) | MAPTMAPK1KMT2AALDH1A1MEN1 | |
| SCHEMBL10048482 | 0.89 | MAPT (0.44) | MAPTMAPK1KMT2AALDH1A1MEN1 | |
| SCHEMBL3928131 | 0.86 | MAPT (0.51) | MAPTMAPK1KMT2AALDH1A1MEN1 | |
| SCHEMBL3928138 | 0.86 | MAPT (0.51) | MAPTMAPK1KMT2AALDH1A1MEN1 | |
| SCHEMBL3922767 | 0.85 | HCAR3 (0.50) | MAPTMAPK1KMT2AALDH1A1MEN1 | |
| SCHEMBL3922764 | 0.85 | HCAR3 (0.50) | MAPTMAPK1KMT2AALDH1A1MEN1 | |
| SCHEMBL3923613 | 0.82 | PTGER4 (0.47) | MAPTKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL585317 | 0.81 | CNR1 (0.45) | MAPTMAPK1KMT2AALDH1A1MEN1 | |
| SCHEMBL10048007 | 0.80 | HTT (0.42) | MAPTMAPK1KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633235-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | NEOMED INSTITUTE (CA) | 2014-01-21 | — | — | US | disclosed |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-7550495-B2 | Compounds, compositions containing them, preparation thereof and uses thereof I | ASTRAZENECA AB (SE) | 2009-06-23 | — | — | US | disclosed |
| EP-1670769-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| EP-1797078-A4 | COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF III | ASTRAZENECA AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| EP-1797077-A4 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| EP-1797076-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1797077-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1797078-A1 | COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF III | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | disclosed |
| US-20060264490-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| EP-1670769-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006033631-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006033630-A1 | COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF III | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006033628-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005030732-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264490-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | F12, C1S, C1R | MAPT 2921/4885MAPK1 4015/4885KMT2A 3673/4885 |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | F12, C1S, C1R | MAPT 2921/4885MAPK1 4015/4885KMT2A 3673/4885 |
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | CYP3A4, CYP2C19, H1-3 | MAPT 3678/4885MAPK1 4037/4885KMT2A 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.